Dosing & Uses
Dosage Forms & Strengths
tablets
- 30mg
- 60mg
- 180mg
oral suspension
- 30mg/5mL
oral disintegrating tablets
- 30mg
Seasonal Allergic Rhinitis/Chronic Idiopathic Urticaria
180 mg PO qDay or 60 mg PO BID
Dosing Modifications
Renal impairment (CrCl <80 mL/min): 60 mg PO qDay initially
Administration
Allegra ODT: Allow to disintegrate on tongue, followed by swallowing with or without water; take on empty stomach; do not chew
Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr
Dosage Forms & Strengths
tablets
- 30mg
- 60mg
- 180mg
oral suspension
- 30mg/5mL
oral disintegrating tablets
- 30mg
Seasonal Allergic Rhinitis
<2 years: Use not recommended
2-12 years: 30 mg PO BID
>12 years: 60 mg PO BID OR 180 mg PO qDay
Allegra ODT
- 6-12 years: 30 mg PO BID
Chronic Idiopathic Urticaria
<6 months: Use not recommended
6 months-2 years: 15 mg PO BID
2-12 years: 30 mg PO BID
>12 years: 60 mg PO BID OR 180 mg PO qDay
Allegra ODT
- 6-12 years: 30 mg PO BID
Dosing Modifications
Renal impairment (CrCl <80mL/min)
- <6 months: Safety and efficacy not established
- 6 months to 2 years: 15 mg PO qDay, initially
- 2-12 years: 30 mg PO qDay, initially
- >12 years: 60 mg PO qDay, initially
Administration
Allegra ODT: Allow to disintegrate on tongue, followed by swallowing with or without water; take on empty stomach; do not chew
Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (1)
- grapefruit
grapefruit will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Contraindicated. Coadministration with grapefruit, apple, or orange juice reduces bioavailability of fexofenadine by inhibiting P-gp; separate administration by at least 4 hr
Serious - Use Alternative (7)
- erdafitinib
erdafitinib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index.
- isocarboxazid
isocarboxazid increases effects of fexofenadine by Other (see comment). Avoid or Use Alternate Drug. Comment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
- lasmiditan
lasmiditan increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
- metoclopramide intranasal
fexofenadine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- sotorasib
sotorasib will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications.
- tepotinib
tepotinib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.
- tranylcypromine
tranylcypromine increases effects of fexofenadine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines.
Monitor Closely (35)
- amifampridine
fexofenadine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- apalutamide
apalutamide will decrease the level or effect of fexofenadine by increasing elimination. Use Caution/Monitor. Apalutamide weakly induces OATP1B1 and may decrease systemic exposure of drugs that are OATP1B1 substrates.
- berotralstat
berotralstat will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered.
- bosutinib
bosutinib increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- crizotinib
crizotinib increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- crofelemer
crofelemer increases levels of fexofenadine by Other (see comment). Use Caution/Monitor. Comment: Crofelemer has the potential to inhibit transporters MRP2 and OATP1A2 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.
- daridorexant
fexofenadine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- diazepam intranasal
diazepam intranasal, fexofenadine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- elagolix
elagolix will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- eliglustat
eliglustat increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.
- eluxadoline
eluxadoline increases levels of fexofenadine by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.
- esketamine intranasal
esketamine intranasal, fexofenadine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- fostamatinib
fostamatinib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Concomitant use of fostamatinib may increase concentrations of P-gp substrates. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib.
- fostemsavir
fostemsavir will increase the level or effect of fexofenadine by Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir.
- gabapentin
gabapentin, fexofenadine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, fexofenadine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- glecaprevir/pibrentasvir
glecaprevir/pibrentasvir will increase the level or effect of fexofenadine by Other (see comment). Use Caution/Monitor. Coadministration with glecaprevir/pibrentasvir may increase plasma concentration of drugs that are substrates of OATP1B1 or OATP1B3
glecaprevir/pibrentasvir will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - istradefylline
istradefylline will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. Consider dose reduction of sensitive P-gp substrates.
- ivacaftor
ivacaftor increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index.
- juice (fruit)
juice (fruit) decreases levels of fexofenadine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Fruit juices inhibit intestinal organic anion transporting polypeptide.
- letermovir
letermovir increases levels of fexofenadine by Other (see comment). Use Caution/Monitor. Comment: Letermovir, an OATP1B1/3 inhibitor may increase plasma concentrations of coadministered OATP1B1/3 substrates.
letermovir increases levels of fexofenadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. - lomitapide
lomitapide increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.
- lonafarnib
lonafarnib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed.
- lurasidone
lurasidone, fexofenadine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- midazolam intranasal
midazolam intranasal, fexofenadine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- nefazodone
nefazodone will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- neratinib
neratinib increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Neratinib inhibits P-gp transport. Caution if coadministered with a P-gp substrate with a narrow therapeutic index.
- phenelzine
phenelzine increases effects of fexofenadine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
- ponatinib
ponatinib increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- pregabalin
pregabalin, fexofenadine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- quinidine
quinidine will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- sarecycline
sarecycline will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors.
- sofosbuvir/velpatasvir
sofosbuvir/velpatasvir increases levels of fexofenadine by Other (see comment). Use Caution/Monitor. Comment: Velpatasvir inhibits OATP1B1, OATP1B3, and OATP2B1 transporters. .
- tucatinib
tucatinib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.
- vemurafenib
vemurafenib increases levels of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
Minor (35)
- amiodarone
amiodarone will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- atorvastatin
atorvastatin will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- clarithromycin
clarithromycin will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- clotrimazole
clotrimazole will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- cyclosporine
cyclosporine will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- dronedarone
dronedarone will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- erythromycin base
erythromycin base will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- erythromycin ethylsuccinate
erythromycin ethylsuccinate will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- erythromycin lactobionate
erythromycin lactobionate will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- erythromycin stearate
erythromycin stearate will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- felodipine
felodipine will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- fosphenytoin
fosphenytoin will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- indinavir
indinavir will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- itraconazole
itraconazole will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- ketoconazole
ketoconazole will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- lapatinib
lapatinib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- loratadine
loratadine will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- lovastatin
lovastatin will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- nicardipine
nicardipine will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- nifedipine
nifedipine will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- nilotinib
nilotinib will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- phenobarbital
phenobarbital will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- phenytoin
phenytoin will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- quercetin
quercetin will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- ranolazine
ranolazine will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- rifampin
rifampin will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- ritonavir
ritonavir will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- simvastatin
simvastatin will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- sirolimus
sirolimus will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- St John's Wort
St John's Wort will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- tacrolimus
tacrolimus will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- tolvaptan
tolvaptan will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- trazodone
trazodone will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- verapamil
verapamil will increase the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- voclosporin
voclosporin will increase the level or effect of fexofenadine by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.
Adverse Effects
Varies in incidence and severity with the individual drug; also, individual patients vary in susceptibility
>10%
Vomiting (6-12%)
1-10%
Headache (5-10%)
Cough (4%)
Diarrhea (3-4%)
URTI (3%)
Back pain (2-3%)
Pyrexia (2%)
Dysmenorrhea (2%)
Dizziness (2%)
Stomach discomfort (2%)
Pain in extremity (2%)
Somnolence (1-3%)
Rhinorrhea (1-2%)
Postmarketing Reports
Sleep disorders (insomnia, paranoia)
Nervousness
Hypersensitivity reactions (anaphylaxis, urticaria, angioedema, chest tightness, dyspnea, flushing, pruritus, rash)
Warnings
Contraindications
Hypersensitivity
Cautions
Allegra ODT contains phenylalanine
Get emergency help if experiencing hives along with symptoms that include trouble swallowing, dizziness or loss of consciousness, drooling, swelling of tongue, swelling in and around the mouth, trouble speaking, wheezing, or problem breathing
The symptoms may be a sign of anaphylactic shock; this condition can be life-threatening if not treated by a healthcare professional immediately
Symptoms of anaphylactic shock may occur when hives first appear or up to a few hours later
If the doctor prescribes epinephrine injections for anaphylaxis, or severe allergy symptoms that could occur with the hives, never use this product as substitute for the epinephrine injection
If prescribed an epinephrine injector, carry it at all times
Do not use to prevent hives from known causes including foods, insect stings, medicines, latex or rubber gloves, because this product will not stop hives from occurring; avoiding the cause of hives is the best way to prevent them
If you do not know the cause of the hives, see a doctor for a medical exam; the doctor may be able to help find the cause
Patients with kidney disease should ask a doctor; the doctor should determine if dose needs to be adjusted
Do not take more than directed
Do not take at the same time as aluminum or magnesium antacids
Do not take with fruit juices
Stop use if allergic reaction to this product occurs; seek medical help right away if symptoms do not improve after 3 days of treatment or the hives have lasted for more than 6 weeks
Pregnancy & Lactation
Pregnancy category: C
Lactation: Excretion in milk unknown; use with caution (AAP states “compatible with nursing”)
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
H1 histamine receptor antagonist; competes for H1-receptor sites in target cells in the respiratory tract, blood vessels, and gastrointestinal tract; major metabolite of terfenadine
Absorption
Duration: ≥12 hr
Peak serum time: 2-3 hr (tablet); 2 hr (ODT); 1 hr (suspension)
Peak plasma concentration: 131 ng/mL
Distribution
Protein bound: 60-70%
Metabolism
Hepatic (5%)
Elimination
Half-life: 14.4 hr (31-72% longer in renal impairment)
Excretion: Feces (80%), urine (11%)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 60 mg tablet |  | |
| fexofenadine oral - | 60 mg tablet |  | |
| fexofenadine oral - | 60 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 60 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 60 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet |  | |
| fexofenadine oral - | 180 mg tablet | | |
| fexofenadine oral - | 30 mg/5 mL suspension |  | |
| Children's Allergy Relief (fexofenadine) oral - | 30 mg/5 mL suspension |  | |
| Aller-ease oral - | 180 mg tablet | | |
| Wal-Fex Allergy oral - | 180 mg tablet | | |
| Wal-Fex Allergy oral - | 60 mg tablet | | |
| Wal-Fex Allergy oral - | 180 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 180 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 180 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 180 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 180 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 60 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 60 mg tablet | | |
| Allergy Relief (fexofenadine) oral - | 180 mg tablet | | |
| Children's Allegra Allergy oral - | 30 mg tablet |  | |
| Children's Allegra Allergy oral - | 30 mg/5 mL suspension |  | |
| Children's Allegra Allergy oral - | 30 mg/5 mL suspension |  | |
| Children's Allegra Allergy oral - | 30 mg/5 mL suspension |  | |
| Allegra Allergy oral - | 60 mg tablet |  | |
| Allegra Allergy oral - | 60 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  | |
| Allegra Allergy oral - | 180 mg tablet |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
fexofenadine oral
FEXOFENADINE 24-HOUR TABLET - ORAL
(FEX-oh-FEN-a-deen)
COMMON BRAND NAME(S): Allegra
USES: Fexofenadine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction.
HOW TO USE: If you are taking the over-the-counter product to self-treat, read all directions on the product package before taking this medication. If you have any questions, consult your pharmacist. If your doctor has prescribed this medication, take it as directed with or without food, usually once daily.Take this medication with water. Do not take with fruit juices (such as apple, grapefruit, or orange) since they may decrease the absorption of this drug.The dosage is based on your age, medical condition, and response to treatment. Do not increase your dose or take this medication more often than directed.Do not take antacids containing aluminum and magnesium within 2 hours of taking this medication. These antacids can decrease the absorption of fexofenadine.Tell your doctor if your condition does not improve or if it worsens.
SIDE EFFECTS: Cough, fever, or stomach upset may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.If your doctor has prescribed this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking fexofenadine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also How to Use section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.This medication may interfere with certain laboratory tests (including allergy skin testing), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Keep all regular medical and laboratory appointments.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Different brands of this medication may have different storage needs. Check the product package for instructions on how to store your brand, or ask your pharmacist. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised December 2021. Copyright(c) 2021 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
